Adagene (ADAG)
(Delayed Data from NSDQ)
$2.80 USD
+0.21 (7.90%)
Updated May 31, 2024 03:58 PM ET
After-Market: $2.72 -0.08 (-2.86%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Adagene Inc. Sponsored ADR [ADAG]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Further Validation of ADG126 in MSS CRC Remains the Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
ADG126 Achieved Proof of Concept in MSS CRC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
ADG153, a Novel CD47-Targted Therapy Worth Your Attention; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
All Eyes on ADG126 Readout in MSS CRC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
CTLA-4 Space Continues to Gain Steam; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Encouraging Sneak Peek at ADG126 Combination Therapy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Another Big Pharma?s Interest Speaks of SAFEbody?s Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Adagene Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
A Versatile Player in Cancer Immunotherapy; Initiate With Buy and a $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
|